Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Evolutionary Genomics's cash to debt ratio for the quarter that ended in Dec. 2022 was 0.15.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Evolutionary Genomicscouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2022.
The historical rank and industry rank for Evolutionary Genomics's Cash-to-Debt or its related term are showing as below:
FNAM's Cash-to-Debt is not ranked *
in the Biotechnology industry.
Industry Median: 6.61 * Ranked among companies with meaningful Cash-to-Debt only.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Evolutionary Genomics Cash-to-Debt Related Terms
Evolutionary Genomics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Evolutionary Genomics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Evolutionary Genomics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolutionary Genomics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evolutionary Genomics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Evolutionary Genomics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolutionary Genomics (FNAM) has a Cash-to-Debt of 0.15 as of Dec. 2022.
Is Evolutionary Genomics' Cash-to-Debt too high?
Evolutionary Genomics' current Cash-to-Debt is 0.15. The Biotechnology industry median Cash-to-Debt is 6.61. Evolutionary Genomics' value of 0.15 is 97.7% below this industry median. Overall, Evolutionary Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Evolutionary Genomics' Cash-to-Debt compare to BXRX and GNCA?
Evolutionary Genomics' Cash-to-Debt of 0.15 can be compared against companies in the Biotechnology industry. The industry median Cash-to-Debt is 6.61. Evolutionary Genomics' value of 0.15 is 97.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.61, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evolutionary Genomics's current Cash-to-Debt of 0.15 is 97.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolutionary Genomics's current Cash-to-Debt is 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolutionary Genomics stock overvalued right now?
Evolutionary Genomics (FNAM) has a current Cash-to-Debt of 0.15. The current Cash-to-Debt is 0.15 and 97.7% below the Biotechnology industry median of 6.61. Evolutionary Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Evolutionary Genomics (FNAM), the current Cash-to-Debt is 0.15 as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
31GF Score
Get the complete analysis for FNAM
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FNAM has been successfully added to your 
